Graticule Asia Macro Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Graticule Asia Macro Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-23,010	Closed	-$1.36M	–	161
2016 Q4	$1.36M	Buy	+23,010	New	+$1.42M	0.16%	78
2016 Q2	–	Sell	-10,512	Closed	-$543K	–	92
2016 Q1	$543K	Buy	10,512 +10,312	+5,156%	+$536K	0.04%	74
2015 Q4	$14K	Hold	200	–	–	﹤0.01%	165
2015 Q3	$12K	Buy	+200	New	+$15.8K	﹤0.01%	90

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Graticule Asia Macro Advisors's XBI Position: Q1 2017 in Review

Graticule Asia Macro Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2017, closing a stake of 23,010 shares — an estimated $1.36M sold.

Graticule Asia Macro Advisors first reported a position in XBI in Q3 2015 and held it in 4 quarters. The position peaked at $1.36M in Q4 2016. 292 funds tracked by Wall St. Rank hold XBI as of Q1 2017.

Graticule Asia Macro Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2017 after selling out during the quarter.
Graticule Asia Macro Advisors sold 23,010 State Street SPDR S&P Biotech ETF shares in Q1 2017, an estimated $1.36M.
Graticule Asia Macro Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2015 and held it in 4 quarters.
Graticule Asia Macro Advisors's State Street SPDR S&P Biotech ETF position peaked at $1.36M in Q4 2016.
292 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2017.

Based on Graticule Asia Macro Advisors's 13F filing for Q1 2017, filed 12 May 2017.